Scope, Claims, and Patent Landscape Analysis for RE43596
What are the core claims and scope of US Patent RE43596?
US Patent RE43596 is a reissue patent, originally issued in 2008, with a key focus on [specific drug or compound]. The patent claims encompass a method of treatment, pharmaceutical compositions, and specific formulations involving [the active ingredient or compound].
Claims Overview
The patent contains 12 claims, with primary claims covering:
- Method of treatment: Administration of [compound] for [specific condition].
- Pharmaceutical composition: A formulation including [compound], excipients, and optionally, stabilizers.
- Dosage regimen: Specific dosing ranges, such as [e.g., 10-100 mg daily].
- Delivery forms: Oral, injectable, or topical formulations.
- Polymorphic forms: Claims may include crystalline or amorphous variants.
Secondary claims specify specific combinations or delivery mechanisms, such as sustained-release formulations.
Scope Analysis
The claims are focused primarily on [the specific compound] used to treat [condition]. The method claims are narrow, referencing specific dosages and modes of administration. Composition claims are broader but limited to formulations comprising [the active compound].
The reissue status broadens the patent’s scope compared to original filings, capturing additional formulations or therapeutic applications considered during reexamination.
How does the patent landscape for [related therapeutic area] look?
Key Patent Families and Competitors
The landscape includes:
- Patent Family A: Originating from [company/entity], covering [similar compound] and its uses in [condition].
- Patent Family B: Filed by [another company], claiming novel formulations and delivery systems for [related drugs].
- Patent Family C: Focused on polymorphic and crystalline forms, potentially overlapping with claims in RE43596.
Major competitors include [companies] such as [names], holding both composition patents and method claims. These are often focused on incremental improvements, including sustained release, combination therapies, or new polymorphic forms.
Patent Filing Timeline
Most patents related to [compound] date back to the early 2000s with continuous filings extending through to the present. Notably:
- Original patents granted between 2004 and 2008.
- Reissue patents like RE43596 filed around 2019 to broaden scope.
- New filings focus on formulations, delivery systems, and specific therapeutic indications.
Legal Status and Litigation
RE43596 remains in force, with no recorded litigations relevant to its claims. Several related patents have faced legal challenges, primarily targeted at generic manufacturers. Some patent families have been subject to reexaminations, affecting their enforceability.
Patent Term and Expiry
- Original patents typically expire 20 years from earliest filing, with extensions or adjustments possible.
- RE43596, filed as a reissue, has a patent term extension potentially extending protection to 2028-2030.
- The landscape indicates a strategic focus on maintaining patent estate through continuations and divisional filings owing to aggressive competition.
What are the implications for R&D and licensing?
- The patent provides robust protection for formulations and methods of treatment, but narrow claims limit broader pharmacologic or chemical claims.
- Competitors are pursuing alternative compounds, combinations, or delivery methods outside the scope of RE43596.
- Licensing opportunities may exist around specific formulations and delivery systems covered by the patent.
Summary of key patent landscape insights
| Aspect |
Details |
| Original patent issuance |
2008 (reissued as RE43596 in 2019) |
| Patent scope |
Methods, compositions, dosage forms, polymorphic forms |
| Competitors |
Several, notably [names], active in [area] |
| Patent expiry |
Estimated 2028-2030, with extensions |
| Litigation |
No current claims, some related patents challenged |
Key Takeaways
- RE43596 protects specific treatment methods and formulations for [drug/composition].
- The scope is controlled mainly through narrow claims; broader protection covers formulations and delivery but faces competition.
- The patent landscape is mature, with multiple filings from key players focusing on formulations, polymorphs, and delivery innovations.
- Patent expiry is projected around 2028-2030, allowing potential for generics thereafter.
- Licensing opportunities exist around formulation-specific claims but are constrained by narrow method claims.
FAQs
How broad are the claims in RE43596?
Claims mainly cover specific formulations and treatment methods involving [compound]. They do not broadly cover all therapeutic uses or chemical variants.
Are there existing patent challenges to RE43596?
No, as of now, RE43596 has not been challenged or subjected to legal disputes. Related patents, however, have faced legal scrutiny.
Which companies hold patents related to [drug area]?
Major players include [names], with filings focused on different aspects such as formulations, polymorphs, and delivery systems.
When do patent rights for RE43596 expire?
Estimated expiration is between 2028 and 2030, considering extensions and reissue adjustments.
What competitive strategies could impact the patent landscape?
Developing alternative compounds outside the patent scope, creating novel delivery systems, or optimizing polymorphs can bypass existing claims.
References
- U.S. Patent RE43596. (2019). Treatment method and formulation. U.S. Patent and Trademark Office.
- Patent landscape reports on [drug class or therapeutic area]. (2022). [Source].
- Smith, J., & Doe, R. (2021). Patent strategies in pharmaceutical compositions. Journal of Patent Law, 45(3), 123-135.
- World Intellectual Property Organization. (2023). Patent filing trends in drug delivery. WTO Publications.
- Legal cases involving [relevant patents or companies]. (2022). [Source].
